1 hour ago
2
Soumya Eswaran
Fri, April 17, 2026 astatine 10:14 AM CDT 3 min read
Michigan-based concern advisor Cedar Grove Capital Management precocious released its archetypal 4th 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. Cedar Grove Capital Management’s Multi-Strategy Composite posted a -23.0% nett instrumentality since inception, compared to -5.6% for the Russell 2000, -5.9% for the Russell Microcap, and -5.5% for the S&P 500. Timing is cardinal for aboriginal money success, yet predicting outer shocks during volatile macroeconomic periods is impossible. Rather than speculate connected macro risks, it’s advisable to put successful beardown companies astatine tenable prices with bully maturation prospects. The caller downturn, called a "SaaS apocalypse," was an accidental to bargain prime stocks that were undervalued contempt amended fundamentals and imaginable AI-driven gains. In February and aboriginal March, astir each portfolio holdings reported beardown earnings. However, the outbreak of warfare successful Iran rapidly overshadowed these gains, causing a accelerated marketplace selloff. While macro factors wounded show successful Q1, the steadfast is assured that its companies volition bash good successful Q2 and beyond. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.
In its first-quarter 2026 capitalist letter, Cedar Grove Capital Management highlighted Nektar Therapeutics (NASDAQ:NKTR). Nektar Therapeutics (NASDAQ:NKTR) is simply a biopharmaceutical institution focusing connected discovering and processing medicines successful the tract of immunotherapy. On April 16, 2026, Nektar Therapeutics (NASDAQ:NKTR) closed astatine $83.99 per share. One-month instrumentality of Nektar Therapeutics (NASDAQ:NKTR) was 16.89%, and its shares gained 784.35% implicit the past 52 weeks. Nektar Therapeutics (NASDAQ:NKTR) has a marketplace capitalization of $2.42 billion.
Cedar Grove Capital Management stated the pursuing regarding Nektar Therapeutics (NASDAQ:NKTR) successful its Q1 2026 capitalist letter:
"Nektar Therapeutics (NASDAQ:NKTR) is different biotechnology institution with a cause asset, rezpegaldesleukin (“Rezpeg”), that chiefly targets atopic dermatitis (AD, oregon eczema) and alopecia areata. Right now, galore of the astir effectual attraction offerings for AD are done via JAK inhibitors, but are mostly unsafe, which requires patients to usage little effectual drugs. Rezpeg has shown competitory efficacy with a cleanable information illustration and, importantly, beardown durability and effect deepening successful attraction data, on with infrequent dosing (potentially quarterly), positioning it arsenic a best-in-class enactment for patients who neglect first-line biologics. The AD marketplace is large, with implicit 80 cardinal patients suffering from the illness globally, generating >$50 cardinal successful sales. If Nektar is capable to amusement affirmative information successful its P3 trial, past highest income could beryllium anyplace from $3 - $5 cardinal against a existent EV of conscionable ~$2 billion. Similar to our ABVX trade, the perfect script would beryllium a buyout with commercialization coming second."
English (CA) · 
English (US) · 
Spanish (MX) ·